However, resistance to EZH2 inhibitors are observed in ARID1A mutant cancers and recent data suggest that the switch of the SWI/SNF catalytic subunits from SMARCA4 to SMARCA2 underlies the acquired resistance to EZH2 inhibitors [208]. Here, EZH2 is linked to cancer.